期刊文献+

23例原发性肝癌介入治疗后副反应和并发症分析及临床防治 被引量:3

ANALYSIS AND PREVENTION ON SIDE-EFFFECT AND COMPLLCATION OF INTERVENTION THERAPY FOR 23 PATIENTS WITH PRIMARY LIVER CARCINOMA
暂未订购
导出
摘要 本文23例原发性肝癌介入治疗后的副反应和并发症主要为全身反应、器官损害及局部出血感染等。临床上以发烧、腹胀、腹痛、恶心、呕吐多见。主要原因与操作质量、化疗栓塞综合症、药物毒性及术后护理等有关。本文对常见并发症及副作用提出临床处理措施。 It has been analyzed that side-effect and complication of intervention treatment for the primary carcinoma of the liver in 23 cases and it consists of general reaction,damaging to the organs hemorrhage and infection in the part. The common symptoms in clinical are fever,distention,abdominal pain, nausea and vomiting. The main cause reason is related to quality of operation, chemotherapy - embolism syndromc, medicine toxicity and nursing after operation. Finally, measurement of the treatment in clinical about presenting side-effect and complication of intervention treatment to the primary carcinoma of the liver have been discussed in the paper
出处 《青海医学院学报》 CAS 1996年第4期247-248,共2页 Journal of Qinghai Medical College
关键词 原发性 肝癌 介入治疗 副反应 并发症 Primary liver carcinoma, Intervention-treatment, Side-effect
  • 相关文献

同被引文献20

  • 1秦叔逵,曹梦苒,钱军,华海清,王琳,何泽明.奥沙利铂为主的FOLFOX方案治疗晚期原发性肝癌[J].临床肿瘤学杂志,2005,10(1):58-60. 被引量:77
  • 2任力飒,杨建平,张宗,王翕,张鸿翔.沙培林对肿瘤坏死因子介导细胞毒的作用[J].肿瘤研究与临床,1995,7(2):73-74. 被引量:3
  • 3纪玉宝,赵蒂勋,徐景浩,王长安,马安伦,张久连.肿瘤免疫活化剂沙培林的研究[J].上海免疫学杂志,1996,16(2):90-93. 被引量:9
  • 4Huang GT,Yang PM,Sheu JC,et al.Intratumor injection of OK-432 for the treatment of small hepatocellular carcimoma[J].Hepatogastroenterology,1990,37(5):452-456.
  • 5Hirakawa M, Gastroduodenal lesions after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma [ J ]. Gastroenterol, 1988;83(8) :837 ~ 40
  • 62013年中国肿瘤年报.
  • 7张应峰.中国临床肿瘤学进展[M].北京:中国协和医科大学出版社,2010:180-185.
  • 8全国肿瘤防治研究办分室,中国抗癌协会.《中国常见恶性肿瘤诊治规范》第二册[M].北京:医科大学、中国协和医科大学联合出版社,1995.
  • 9Qin SK, Bai Y. Phase III study of oxaliplatin plus 5-fluorouracil/leu- covorin (Folfox4) versus doxorublcin as palliative systemic chemothera- py in advanced HCC in Asian patients[J].Journal of Clinical Oncology, 2010,28:7s.
  • 10Patt YZ, Baron AD, Parks VA, et al. Phase II trial of gemcitabine(G), oxaliplatin(O), and erlotinib (T) for the treatment of hepatocellular car- cinoma (HCC) and biliary tree cancers(BTC)[J].Journal of Clinical On- cology, 2010,28:7s.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部